Baliospermum (Baliospermum montanum / Baliospermum solanifolium): A Comprehensive Reference
1. Identity, Taxonomy, and Botanical Description
Baliospermum solanifolium, synonym Baliospermum montanum, is a plant in the family Euphorbiaceae. The currently accepted botanical name according to the Royal Botanic Gardens, Kew (Plants of the World Online) is Baliospermum solanifolium (Burm.) Suresh, with Baliospermum montanum (Willd.) Müll.Arg. treated as a widely used synonym; the latter binomial was formally described by Johannes Müller Argoviensis in De Candolle's Prodromus (vol. 15, 1866). Additional synonyms recorded in botanical literature include Baliospermum axillare Blume and Jatropha montana Willd.
The plant is commonly known as red physic nut, wild castor, wild croton, or wild sultan seed. In Ayurvedic and Sanskrit traditions the plant is most frequently called Danti; it is a commonly used plant in both the Ayurveda and traditional medicine system of Sri Lanka, where it is also known as "Detta" in Sinhala and "Danti" in Sanskrit. Regional vernacular names include Harun or Haphun (Bengali), Niradimuthi (Tamil), Cinna Nepalam (Telugu), and Danti (Marathi and Hindi).
Baliospermum solanifolium is a stout under-shrub 0.9–1.8 m in height with herbaceous branches from the roots. Leaves are simple, sinuate-toothed, upper ones small, lower ones large and sometimes palmately 3–5 lobed. Flowers are numerous, arranged in axillary racemes with male flowers above and a few females below. Fruits are capsules, 8–13 mm long and obovoid. Seeds are ellipsoid, smooth, and mottled.
The species is distributed from China to tropical Asia. It is found throughout the sub-Himalayan tracts from the Khasi Hills to Kashmir, and is common in Bihar, West Bengal, and Peninsular and Central India. The plant is also distributed throughout Nepal, Burma, and Malaya.
The overexploitation of this plant's root for its numerous traditional uses has led to its red-list classification as an endangered species. Conservation efforts have prompted research into micropropagation and cryopreservation as strategies for long-term sustainable utilization of this important medicinal plant.
2. Common Forms and Preparations
According to Ayurvedic texts, roots, leaves, seeds, and seed oil of Baliospermum montanum are mostly used. In classical Ayurvedic practice, the root (often called Dantimool) is the most pharmacologically valued part. Decoction of leaves is reported to be useful in asthma, and expressed juice of young leaves is applied to bleeding cuts while leaves are applied as a bandage to stop haemorrhage, prevent suppuration, and heal wounds. The seeds are used as a drastic purgative and seed oil as a powerful hydragogue cathartic and applied externally in rheumatism.
Classical Ayurvedic dosage forms incorporating Danti include kalka (paste), taila (oil), lepa (topical application), varti, churna (powder), kwatha (decoction), vati (tablet/pill), arka (distillate), ghrita (ghee preparation), and nashya (nasal formulation). The roots of Baliospermum montanum are an essential ingredient in Ayurvedic formulations such as Dantyarista.
In modern phytopharmacological research, the plant has been extracted and tested in numerous solvent systems including ethanol, methanol, aqueous, ethyl acetate, and chloroform extracts, and has also been formulated as nanoparticles for experimental use. Externally, the paste of roots and seeds is used in oedema and pain, and the root paste is applied on painful edema and hemorrhoids.
An important consideration specific to Ayurvedic practice is that as per Ayurveda, the roots are considered toxic and are therefore used after purification for medicinal purposes. According to Charaka, for the purification of Dantimool, danti roots are coated in a paste of pippali and madhuka, after which this mass is wrapped in grass, tied, and wrapped under a mud covering — a classical detoxification process referred to as putpak.
3. Traditional and Historical Use
3.1 Ayurvedic Tradition (India)
Baliospermum montanum has one of the longest and most extensively documented histories of use in classical Indian medicine. The plant, known as Danti, is mentioned as far back as the Charaka Samhita (circa 1st–2nd century CE), labelled under "Kapha-vatahara" herbs that pacify kapha and vata doshas. The Sushruta Samhita praised its efficacy as a digestion stimulant and mild purgative.
In the Charaka Samhita, Danti is placed within the Bhedaniya group — herbs used in purgation — and the Mulini dravyas group — herbs having the root as the mainly used part. In the Sushruta Samhita it is placed within the Shyamadi and Adhobhagahara groups, useful in Virechana (elimination of morbid toxins via the rectal route), and Vagbhata also lists it under the Shyamadi group.
The plant appears extensively across the classical canon. Information from classical texts including the Charaka Samhita, Sushruta Samhita, Ashtanga Samgraha, Ashtanga Hridaya, Kashyapa Samhita, Bhela Samhita, Harita Samhita, Vrindamadhava, Chakradutta, Vangasena Samhita, Sharangdhara Samhita, Bhavaprakasha Samhita, Yogaratnakara, Bhaishajya Ratnavali, and Bharata Bhaisajya Ratnakara all make reference to Danti as a single drug or as a content in multi-ingredient formulations.
A review of sixty Ayurvedic pharmacopoeias found about 132 formulations containing Danti as an ingredient, indicated in almost 28 varied disease conditions. These conditions span from digestive and hepatic disorders to dermatological and parasitic ailments. The Charaka Samhita includes Baliospermum montanum under the Krimi Cikitsa Adhyaya (chapter on worm/parasite treatment). Snuff prepared with rock salt, Danti, Marica, Pippali, Karanja fruit and Vidanga is described as destroying worms, skin diseases (Kushta), and disorders of Kapha. Ghrita (ghee preparation) prepared from Danti is described as effective in the treatment of worms and Kushta.
In Ayurvedic pharmacological terms, the pharmacological properties of Baliospermum montanum are described as Katu Rasa (pungent taste), Guru Theekshna Guna (heavy and sharp qualities), Katu Vipaka (pungent post-digestive effect), Ushna Veerya (hot potency), and Kapha Pitta Shamaka action. The primary Prabhava (special action) is purgation. Other Ayurvedic medicinal properties attributed include Ashukari, Vikasi, Krimihara, Kushtahara, Kaphahara, Vatahara, Dushta Vrana Shodhana, Udara, Arshoghna, Ashmarihara, Shoolahara, Deepana, Pachana, Shodhana, Sara, Anahahara, Shophahara, Vidahahara, Kanduhara, Pleehahara, and Gulmahara.
Danti is classified as a Tikshna Virechana Dravya (strong purgative herb) in Ayurveda and is commonly used in Panchakarma therapies for deep detoxification. The plant is sold under various Ayurvedic names including "Danti," "Dravanti," and "Hastidanti," and on the basis of botanical studies it was established that "Danti" refers specifically to Baliospermum montanum.
3.2 Traditional Use in Sri Lanka
The plant is a commonly used drug in both the Ayurveda and the traditional medicine system in Sri Lanka. In Sri Lankan traditional medicine (Hela Wedakama), the root's decoction was administered to women post-childbirth to ease bowel movements — a practice that has persisted alongside occasional warnings about excess doses causing loose stools.
3.3 Traditional Use in Thailand and Southeast Asia
The root of Baliospermum montanum has been used as an ingredient of traditional Thai medicines for the treatments of several diseases including itching eczema, muscle and joint inflammation, and cancer. The plant's range across Southeast Asia, including Burma and Malaya, reflects its broad regional employment across multiple traditional medicine systems.
3.4 Ethnobotanical Uses
In Ayurveda, roots of the plant are reported to be useful in jaundice, and in the traditional system of medicine are highly valued for treatment of leucoderma, piles, wounds, anaemia, itching, pains, and inflammations, and are reputed as an anthelmintic. Various parts of Baliospermum montanum have been traditionally used to treat diseases including leprosy, bleeding disorders, abdominal pain, calculi, itching, hemorrhoids, worm infestation, burning sensations, inflammation, abdominal disorders, and tumors. The roots are used as a laxative to treat dropsy, jaundice, anasarca, rheumatism, and anaemia, as well as skin diseases, piles, and leucoderma.
In traditional oncological applications, a paste containing B. montanum, Plumbago zeylanica, Euphorbia neriifolia, Calotropis procera, Semecarpus anacardium, and jaggery was applied over tumors for treatment. B. montanum has been in use since ancient times for the treatment of abdominal tumors.
4. Key Constituents and Active Compounds
4.1 Overview of Phytochemical Classes
Compounds isolated from this plant include steroids, triterpenoids, diterpenes, glycosides, saponins, alkaloids, and polyphenols. The plant B. montanum possesses chemical constituents such as flavonoids, glycosides, sterols, steroids, and terpenoids. Quantitative phytochemical profiling across different plant parts has revealed a rich matrix of bioactive compounds. Qualitative study of alkaloids, carbohydrates, glycosides, steroids, flavonoids, coumarins, saponins, fatty acids, tannins, proteins and amino acids, gums and mucilage, terpenoids, anthraquinones, and phenols showed variable results in different solvents. Quantitative estimation revealed phytochemicals in the following ranges: alkaloids (6.2–9.5%), flavonoids (35.63–43.33%), saponins (9.9–13.2%), phenolics (38.43–43.44%), tannins (13.26–18.3%), and terpenoids (25.36–33.4%).
4.2 Signature Diterpenoid Phorbol Esters (Root)
The most pharmacologically significant and toxicologically relevant constituents are a group of phorbol esters concentrated in the root. Five phorbol esters — montanin, baliospermin, 12-deoxyphorbol-13-palmitate, 12-deoxy-5β-hydroxyphorbol-13-myristate, and 12-deoxy-16-hydroxyphorbol-13-palmitate — were isolated from B. montanum roots. The important compounds reported from B. montanum are 12-deoxyphorbol-13-palmitate, 12-deoxy-5β-hydroxyphorbol-13-myristate, montanin, baliospermin, and axillarenic acid.
An investigation of the constituents responsible for the antitumor activity observed for extracts of Baliospermum montanum roots yielded five new phorbol ester derivatives exhibiting anticancer activity. Of these, montanin was found to be closely related to huratoxin, and baliospermin to mancinellin. Evidence for the structures of the other isolates — 12-deoxyphorbol 13-palmitate, 12-deoxy-5β-hydroxyphorbol-13-myristate, and 12-deoxy-16-hydroxyphorbol-13-palmitate — was obtained by correlation with known compounds and preparation of derivatives.
A non-vicinal dihydroxy mono-saturated acid was isolated from the seed oil and characterized as 11,13-dihydroxytetracosan-9-enoic acid, designated as axillarenic acid. Leaves contain β-sitosterol β-D-glucoside and hexacosanol. The leaves showed the presence of steroids, terpenoids, and flavonoids, and absence of alkaloids and saponins.
4.3 Polyphenolic Constituents
Epiafzelechin and two propelargonidins have been reported for the first time in B. montanum active leaf fractions. Afzelechin-(4α→8)-afzelechin was found to be a dual inhibitor of COX-2/15-LOX and NO production. Phytochemical analysis has identified flavonoids, phenolic compounds, and other bioactive constituents. The presence of flavonoids in methanol extract and its methanol fraction may be responsible for hepatoprotective properties.
4.4 Endophytic Fungal Metabolites
In a study investigating endophytic fungi, 203 endophytic fungi representing twenty-nine species were isolated from tissues of B. montanum. Colonization and isolation rates were higher in stem, followed by seed, root, leaf, and flower. Phytochemical analysis revealed that 70% of endophytic isolates showed alkaloids and flavonoids, while 13% were positive for phenols, saponins, and terpenoids. These endophytes also produced notable extracellular enzymes such as amylase, cellulase, phosphatases, protease, and lipase.
5. Established Mechanisms of Action
Several mechanisms have been proposed and partially characterized at the preclinical level, predominantly through in vitro studies:
- Purgative / Cathartic Action: The phorbol ester constituents of the root are considered responsible for the well-documented laxative and purgative effects. The seed oil's hydragogue cathartic action is attributed to its lipid constituents. These act by stimulating intestinal motility and secretion.
- Anti-inflammatory (COX-2 / 15-LOX / NO Inhibition): Research has investigated the anti-inflammatory potential of various solvent extracts, fractions, and bioactivity-guided isolated compounds from B. montanum through COX-2 and 15-LOX inhibition, and NO production inhibition, as well as evaluation of antioxidant, total phenolic, and flavonoid contents. The compound afzelechin-(4α→8)-afzelechin was found to be a dual inhibitor of COX-2/15-LOX and NO production.
- Antioxidant / Free Radical Scavenging: Antioxidant activity of methanolic leaf extract was evaluated using DPPH radical scavenging and ABTS decolouration assays. Total phenolic content was high in this extract, and antioxidant potential was well established with the DPPH assay, providing a scientific basis for the traditional use of this plant in medicines. In antihyperlipidemic and antioxidant studies, the ethyl acetate fraction showed the lowest IC50 values, indicating the strongest antioxidant activity.
- Immunomodulatory (Neutrophil Activation): A preliminary study revealed that Baliospermum montanum extract stimulated chemotactic, phagocytic, and intracellular killing potency of human neutrophils. The aqueous extract of B. montanum was found to stimulate the cell-mediated immune system by increasing neutrophil function.
- Antitumour (Phorbol Ester-Mediated Cytotoxicity): An aqueous alcoholic extract of the root of B. montanum exhibited activity against the P-388 lymphocytic leukemia in vivo. The isolated phorbol esters are credited as the primary cytotoxic agents.
- Hepatoprotection (Flavonoid-Mediated): The presence of flavonoids in the methanol extract and its methanol fraction may be responsible for hepatoprotective properties. High-performance thin-layer chromatography profiling of flavonoids used quercetin-3-O-galactosyl-7-O-rhamnoside as a marker, and results indicated hepatoprotective properties of the methanol extract.
- Lipid-Lowering (HMG-CoA Reductase / Lipase Inhibition): In molecular docking studies, baliospermin and montanin were found to have the highest binding affinity for HMG-CoA reductase and lipase, respectively, suggesting a potential mechanism for antihyperlipidemic activity.
6. Scientific Evidence by Area of Use
Important caveat: There is a near-total absence of human clinical trials evaluating Baliospermum montanum. The entirety of the current evidence base derives from in vitro (cell culture) studies, in vivo animal experiments, and computational (in silico) studies. No randomised controlled trials in human subjects have been published and indexed in major scientific databases to date. All findings below must be interpreted in this context.
6.1 Anthelmintic Activity
Evidence level: In vitro only; preliminary.
Alcohol and aqueous extracts from the roots of Baliospermum montanum were investigated for anthelmintic activity against Pheretima posthuma and Ascardia galli. Various concentrations (10–100 mg/mL) of each extract were tested in a bioassay involving determination of time of paralysis and time of death of the worms. Both extracts exhibited significant anthelmintic activity at the highest concentration of 100 mg/mL.
Both extracts showed anthelmintic activities in a dose-dependent manner, with the shortest time of paralysis and death recorded at 100 mg/mL for both types of worms. The alcoholic extract caused paralysis in 10 minutes and death in 28 minutes, while the aqueous extract showed paralysis in 9 minutes and death in 30 minutes against the earthworm P. posthuma. The reference drug piperazine citrate showed paralysis at 21 minutes and death at 59 minutes under the same experimental conditions, meaning the plant extracts outperformed the standard at the highest concentration in this model. These findings are in vitro only, using earthworm and poultry roundworm models; clinical relevance to human parasitic infections remains unestablished.
6.2 Anti-inflammatory Activity
Evidence level: In vitro only; preliminary but mechanistically specific.
Baliospermum montanum is traditionally used to treat various ailments including inflammation, rheumatoid arthritis, and pain. The root part is well documented for anti-inflammatory activity. A published study evaluated the multitargeted anti-inflammatory activity of the less-explored leaf part, representing the first study investigating the COX-2/15-LOX dual inhibiting potential and NO production inhibition of BM leaf extracts, fractions, and compounds.
The leaf's water, ethanol, and hydroethanolic extracts were evaluated for anti-inflammatory activity by assessing inhibition of COX-2, 15-LOX, and NO production. Additionally, antioxidant potential was determined through DPPH, ABTS, and FRAP assays. The most active ethanol extract was fractionated into 12 fractions and tested for anti-inflammatory and antioxidant activities, as well as phenol and flavonoid content. Ethanol extract and ethyl acetate fractions showed multi-target therapeutic potential. Epiafzelechin and two propelargonidins were reported for the first time in BM active fractions. Afzelechin-(4α→8)-afzelechin was found to be a dual inhibitor of COX-2/15-LOX and NO production. These are exclusively cell-based (in vitro) findings.
6.3 Anticancer / Cytotoxic Activity
Evidence level: In vitro and limited in vivo (animal); no human data.
Anticancer potential was one of the earliest areas of scientific investigation for this plant. An aqueous alcoholic extract of the root exhibited activity against the P-388 lymphocytic leukemia in vivo. No previous biological or phytochemical results had been reported previously for a member of the genus Baliospermum at the time of the initial investigation.
In vitro cytotoxic activity against the HT-29 (human colon cancer) cell line at different concentrations was evaluated, and the IC50 value calculated was below 50 µg/mL, indicating the potentiality of Baliospermum montanum Muell. Arg. extracts. An aqueous alcoholic extract of the root of B. montanum also exhibited activity against P-388 lymphocytic leukemia in vivo.
A more recent nanomedicine approach further characterized anticancer potential. Baliospermum montanum is used in Ayurveda for the treatment of cancer, and the plant has been studied to possess various constituents responsible for its anticancer activity. Stable nanoparticles of B. montanum were prepared from both aqueous and ethanolic extracts, and cytotoxic effects were studied on prostate cancer and normal cell lines. Size analysis by DLS and SEM revealed an average size of 100±50 nm and 150±50 nm for nanoparticles prepared from aqueous and ethanolic extracts, respectively.
Nanoparticles prepared with both aqueous and ethanolic extracts of B. montanum presented a dose- and time-dependent toxicity on prostate cancer cells, with cell viability of 22% and 6% at the maximum concentration of aqueous and ethanolic nanoparticles (2 mg/mL), respectively, at 48 hours. Additionally, no in vitro haemolysis and a significant reduction of the wound healing capacity and colony-forming ability of prostate cancer cells were demonstrated. The B. montanum extract nanoparticles were cytotoxic against PC3 prostate cancer cells but did not show growth inhibition against normal mouse embryonic fibroblasts (NIH3T3). All findings are in vitro; no human oncological trials exist.
Aqueous and alcoholic extracts of the plant have also shown cytotoxic activity on HT-29 human colon cancer cell lines.
6.4 Hepatoprotective Activity
Evidence level: Animal (in vivo) and in vitro; no human data.
Preliminary studies on roots of B. montanum showed significant hepatoprotective activity of total methanol extract (ME) at a dose level of 200 mg/kg against carbon tetrachloride-induced hepatotoxicity.
A subsequent activity-guided fractionation study explored this further. Evaluation of hepatoprotective effect of ethyl methyl ketone and methanol sub-fractions obtained from the methanol fraction of total methanol extract was carried out both in vivo and in vitro using paracetamol-induced toxicity. Hepatoprotective activity in vivo was assessed by determining serum levels of GOT, GPT, alkaline phosphatase, total bilirubin, total cholesterol, total protein, and albumin. The studies were supported by histopathological examination of liver sections. In vitro activity was assessed by determining the change in hepatocyte viability and parameters such as GOT, GPT, and total protein.
The methanol sub-fraction prevented hepatic damage in vivo induced by paracetamol, while both sub-fractions showed hepatoprotective effect by restoring altered parameters in the selected in vitro model. The results were comparable with the standard hepatoprotective drug silymarin. This study underlines the therapeutic potential of B. montanum as per claims in Ayurveda in liver disorders. The Euphorbiaceae family includes multiple plants with hepatoprotective properties, with Baliospermum montanum identified as one such plant from this family.
6.5 Anti-allergic Activity
Evidence level: In vitro only; preliminary.
A Thai research group isolated major compounds of the crude ethanolic extract of B. montanum root, developed and validated an HPLC method for determination of major components, and then investigated anti-allergic, anti-inflammatory, and cytotoxic activities of the extract. The anti-allergic activity was assessed using the inhibitory effect of β-hexosaminidase released from RBL-2H3 cells, inhibition of nitric oxide production from RAW 264.7 cells, and cytotoxic activity against cancerous liver cell lines (HepG2 and KKU M156) by SRB assay. Investigation of several associated biological activities was noted to be necessary before further development, and minor active compounds remained to be isolated with a more sensitive analytical method to detail the key responsive components.
6.6 Antioxidant Activity
Evidence level: In vitro only; well-characterized but clinically unvalidated.
The main objective of several studies has been to investigate phytochemical and antioxidant activities to justify the traditional use of this plant in medicines. Antioxidant activity of methanolic leaf extract was evaluated with total phenolic determination, DPPH radical scavenging assay, and ABTS decolouration assay. The total phenolic content was found to be high in this extract, and antioxidant potential was well established with DPPH, providing a basis for the traditional use of this plant in medicines. The ethyl acetate fraction showed the lowest IC50 values, indicating the strongest antioxidant activity, and exhibited the highest antihyperlipidemic potential. This study highlights the phytochemical composition of B. montanum roots and underscores the significant antioxidant and antihyperlipidemic properties of its fractions.
6.7 Immunomodulatory Activity
Evidence level: In vitro (human neutrophils); preliminary.
Aqueous extract of roots of Baliospermum montanum was evaluated for immunomodulatory activity by studying neutrophil phagocytic function. Different concentrations (25, 50, and 100 µg/mL) of aqueous root extract were subjected to study in vitro methods of phagocytosis including neutrophil locomotion, chemotaxis, immunostimulant activity of phagocytosis of killed Candida albicans, and qualitative nitroblue tetrazolium test using human neutrophils.
This preliminary study revealed that Baliospermum montanum extract stimulated chemotactic, phagocytic, and intracellular killing potency of human neutrophils at different concentrations. The aqueous extract stimulated the cell-mediated immune system by increasing neutrophil function. The study employed isolated human neutrophils (not a whole-organism model), and no clinical immunological trials have been conducted.
6.8 Antihyperlipidemic Activity
Evidence level: In silico (computational) and in vitro; highly preliminary.
Molecular docking revealed that baliospermin and montanin had the highest binding affinity for HMG-CoA reductase and lipase, respectively. The ethyl acetate fraction showed the lowest IC50 values for antioxidant activity and exhibited the highest antihyperlipidemic potential. These are computational and in vitro findings with no corroborating clinical data.
7. Body Systems and Health Areas
Across traditional use records, ethnobotanical surveys, and experimental research, Baliospermum montanum has been associated with the following body systems and health domains:
- Gastrointestinal system: The plant induces diarrhoea and is therapeutically associated with constipation, disorders of the digestive system. It is the primary system of classical Ayurvedic use. Disorders cited include constipation, hemorrhoids (piles), abdominal pain, intestinal worms, ascites, and liver dysfunction.
- Hepatic system: In Ayurveda, roots of the plant are reported to be useful in jaundice. Preclinical studies have demonstrated hepatoprotective activity against chemical liver toxicity models, with results comparable to silymarin in one study.
- Integumentary system (skin): The plant is therapeutically associated with leucoderma, skin disease. Traditional topical uses include eczema, wound healing, suppuration, and hemorrhoids.
- Respiratory system: Decoction of leaves is reported to be useful in asthma. Traditional use for bronchitis has also been recorded.
- Musculoskeletal system: The root has been used in traditional Thai medicines for muscle and joint inflammation. Seed oil has been applied externally in rheumatism.
- Immune system: In vitro evidence supports stimulation of neutrophil-mediated immunity.
- Oncological associations: Traditional use for abdominal tumors and experimental in vitro cytotoxic activity against multiple cancer cell lines (colon, liver, prostate, lymphocytic leukemia) have been documented.
- Urinary system: The plant's roots are considered diuretic in traditional practice, and urinary calculi (kidney stones) are listed among its indications in classical texts.
- Haematological / Circulatory system: Therapeutic association with anaemia and disorders of the circulatory system are recorded in Ayurvedic tradition.
8. Dosage Forms and Doses Reported in Studies
No standardized human clinical dose has been established. The following doses are those reported in preclinical studies only, reproduced exactly as stated in those sources:
- Anthelmintic study (in vitro): Various concentrations from 10 to 100 mg/mL of each extract were tested in the bioassay. Both extracts exhibited significant anthelmintic activity at the highest concentration of 100 mg/mL.
- Hepatoprotective study (in vivo, animal): Preliminary studies showed significant hepatoprotective activity of total methanol extract at a dose level of 200 mg/kg against carbon tetrachloride-induced hepatotoxicity.
- Immunomodulatory study (in vitro, human neutrophils): Different concentrations of 25, 50, and 100 µg/mL of aqueous root extract were used to study neutrophil phagocytic function.
- Prostate cancer nanomedicine (in vitro): Nanoparticles presented dose- and time-dependent toxicity on prostate cancer cells, with cell viability of 22% and 6% at a maximum concentration of aqueous and ethanolic nanoparticles of 2 mg/mL, respectively, at 48 hours.
- Nanoparticle size (in vitro): Size analysis by DLS and SEM revealed an average size of 100±50 nm and 150±50 nm for nanoparticles prepared from aqueous and ethanolic extract, respectively.
In Ayurvedic classical formulations, dosage forms include kalka (paste), taila (oil), lepa (topical application), varti, churna (powder), kwatha (decoction), vati (tablet/pill), arka (distillate), ghee preparations, and nashya (nasal formulation), with specific quantities varying by formulation and classical text. No universally validated dose for any of these preparations has been established in controlled human trials.
9. Safety Considerations
9.1 Phorbol Ester Toxicity
The most significant and well-characterized safety concern with Baliospermum montanum is the presence of phorbol esters in the root. Currently, five types of phorbol esters are reported in the root of Baliospermum montanum. One research group observed the presence of phorbol-12-myristate-13-acetate (PMA; C36H56O8) in the root — an additional phorbol ester whose carcinogenic property restricts its use in food or medicine. No specific method has been reported that can remove or disintegrate phorbol esters in Baliospermum montanum root.
Phorbol esters as a chemical class are known protein kinase C (PKC) activators and promoters of tumour formation. Their presence in B. montanum root creates a fundamental tension: while the plant-specific phorbol esters (montanin, baliospermin, and related compounds) have shown anticancer activity in some experimental models, the concomitant detection of PMA — a known tumour promoter — raises significant safety flags for unsupervised use.
9.2 Ayurvedic Requirement for Purification (Shodhana)
As per Ayurveda, roots are considered toxic and are used only after purification for medicinal purposes. The traditional "putpak" method (similar to a traditional oven method) was employed in classical practice to detoxify the raw sample of B. montanum root. This detoxification requirement — documented in classical texts and attributed to Acharya Charaka — reflects a long-standing recognition of the plant's potential for harm when used in unpurified form.
9.3 Purgative Potential and Dose-Related Gastrointestinal Effects
The plant is classified as a Tikshna Virechana Dravya (intense purgative herb) in Ayurveda, used extensively in Ayurvedic cleansing therapies. This intense purgative action means that use outside supervised Panchakarma settings, or at excessive doses, can result in pronounced diarrhoea, dehydration, and electrolyte disturbances. In the Sri Lankan tradition, the root decoction has been associated with occasional warnings about excess doses causing loose stools.
9.4 Adulteration and Market Quality
A market survey revealed that genuine Danti is not being sold in the market, and samples were found to be pieces of the stem of Jatropha curcas and Ricinus communis. Both of these substitute species carry their own distinct toxicological profiles, highlighting a quality and safety concern for consumers and practitioners who cannot authenticate botanical identity.
9.5 Conservation Status
The overexploitation of this plant's root for its numerous traditional uses has led to its red-list classification as an endangered species. This has implications for both sourcing reliability and the ecological sustainability of continued commercial or medicinal collection.
9.6 Absence of Human Safety Data
No formal human toxicological studies, pharmacokinetic profiling in humans, or clinical safety trials have been published. The absence of controlled human data means that drug interaction potential, contraindicated populations (e.g., pregnancy, paediatric use, hepatic impairment), and maximum tolerated dose in humans remain formally uncharacterised. Investigation of several associated biological activities is noted to be necessary before further development of the plant as a therapeutic agent can proceed.
10. Summary of Evidence Strength
The following table summarizes the quality of evidence across therapeutic claims for Baliospermum montanum:
- Purgative / laxative action: Supported by extensive and historically consistent traditional records across multiple traditions and classical texts. No controlled human trials.
- Anthelmintic activity: Demonstrated in vitro (earthworm and poultry roundworm models); no human parasite data.
- Anti-inflammatory: Mechanistically characterized in vitro (COX-2, 15-LOX, NO inhibition); no animal models for the leaf constituents and no human studies.
- Anticancer / cytotoxic: Demonstrated in vitro against multiple human cell lines and one in vivo animal leukemia model; no human oncological data.
- Hepatoprotective: Demonstrated in vitro and in vivo (rat models using paracetamol and CCl4 models); comparable to silymarin in one animal study; no human data.
- Antioxidant: Well demonstrated in vitro (DPPH, ABTS assays); no clinical relevance established.
- Immunomodulatory: Shown in vitro using isolated human neutrophils; no whole-organism or clinical data.
- Antihyperlipidemic: In silico docking and in vitro evidence only; highly preliminary.
Overall: All scientific evidence for Baliospermum montanum remains preclinical. No area of use has been validated by human clinical trials. The evidence base is primarily constituted by in vitro studies, with a smaller number of animal studies, and computational modelling. The traditional use record is deep and cross-cultural, but this does not substitute for controlled clinical evidence of safety or efficacy.
References
Go back